ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Immunai has raised $60 million in series A financing to develop immunotherapies by studying the immune system at the single-cell level. The company says the financing brings its total funding to $80 million, which it will use to expand its cell database and improve its work in reprogramming immune cells. Immunai recently partnered with Baylor College of Medicine to analyze genetically engineered natural killer immune cells being tested in clinical trials for neuroblastoma.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter